Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis.

Autor:	Hayat, Sawsan J., Uppal, Sukhbir S., Narayanan Nampoory, M. R., Johny, Kaivilayil V., Gupta, Ramkumar, Al-Oun, Mohammed
Předmět:	LUPUS erythematosus SERUM CYTOKINES MONOCLONAL antibody probes CYCLOSPORINE KIDNEY diseases
Zdroj:	Clinical Rheumatology; Jun2007, Vol. 26 Issue 6, p973-975, 3p
Abstrakt:	Because disease activity in systemic lupus erythematosus correlates well with increased serum levels and activity of the cytokine tumor necrosis factor alpha (TNF-α), we report on the safety and efficacy of infliximab, a chimeric monoclonal antibody directed against TNF-α, given to a patient with active lupus with diffuse proliferative nephritis (WHO Class IV). This patient who failed to remit with a combination of full-dose steroids, mycophenolate mofetil, and cyclosporine, went into sustained remission with the addition of infliximab infusions. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink